Loading...
Loading...
Cowen and Company analyst Simos Simeonidis upgraded Vivus
VVUS from market perform to outperform and raised the PT from $13.50 to $19.
Simeonidis reported that the risk/ reward associated with Vivus “appears compelling” as management changes and retail availability of Qsymia suggest a “significant upside” from current price levels. The diet pill Qsymia is a market leader supplying 60% of the obesity market.
In the note, the analyst rates Arena Pharmaceuticals
ARNA as new market perform with a PT of $4.50. Simeonidis also initiated Orexigen Therapeutics
OREX with an outperform rating and PT of $10.
Vivus closed at $10.19 on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in